Bio-Techne Launches Expanded RNAscope Probe Portfolio
Bio-Techne (NASDAQ: TECH), a pioneer in life science tools and reagents, has recently unveiled an extended collection of RNAscope™ in situ hybridization probes. This move significantly enhances research capabilities in spatial biology, crucial for advancing next-generation therapeutics and diagnostics. The enhanced RNAscope probe portfolio now boasts over 70,000 unique probes, covering more than 450 species, emphasizing Bio-Techne's commitment to boosting scientific research efficiency.
Revolutionizing Spatial Biology Research
The RNAscope technology stands at the forefront of spatial biology, offering researchers an unparalleled view of disease pathology at the single-cell level. This capability allows for a deeper understanding of therapeutic responses across various diseases. By providing superior sensitivity and specificity, the RNAscope probes enable scientists to conduct precise investigations that can inform both research and clinical applications.
Accelerating Validation of RNA Biomarkers
Implementing the newly added probes is straightforward, allowing researchers to fast-track the validation of RNA biomarkers sourced from single-cell genomics and spatial discovery projects. The comprehensive RNAscope probe guarantee reassures customers about the quality and reliability of their selections, facilitating user confidence in their research breakthroughs.
Integrating Probes with Antibodies for Deeper Insights
Customers have the option to purchase RNAscope probes alongside R&D Systems antibodies, enhancing the ability to observe and interpret changes in cell phenotypes and functional states. The availability of both manual and automated formats further streamlines the research process, particularly for those utilizing advanced systems such as the Lunaphore COMET™, enabling a seamless transition from discovery to practical applications.
Commitment to Translational Research and Precision Medicine
Dr. Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment, expressed the company’s mission, stating, “Empowering our customers with precise and scalable solutions to advance translational research and precision medicine is central to our mission.” With over 12,000 citations in relevant studies, the latest additions to the RNAscope portfolio serve to enhance biomarker validation and improve patient outcomes.
About Bio-Techne Corporation
Bio-Techne Corporation (NASDAQ: TECH) is a global leader in the life sciences industry, known for providing innovative tools and bioactive reagents that support both research and clinical diagnostics. These products are essential for scientific exploration into biological mechanisms and disease processes, significantly aiding drug discovery and clinical testing initiatives. With an extensive product range and revenues reaching approximately $1.2 billion in the recent fiscal year, Bio-Techne employs a dedicated team of around 3,100 global staff.
Stay Connected with Bio-Techne
For a comprehensive overview of Bio-Techne's offerings and updates, visit their official website. The company actively engages users through various social media platforms, ensuring a strong community connection and sharing of scientific advancements.
Frequently Asked Questions
What are RNAscope probes used for?
RNAscope probes are utilized in spatial biology to gain detailed insights into RNA expression in single cells, vital for understanding disease mechanisms.
How many unique probes does the new RNAscope portfolio offer?
The expanded RNAscope portfolio now includes over 70,000 unique probes across more than 450 species.
What areas of research can benefit from RNAscope technology?
RNAscope technology benefits various fields, including cancer research, neuroscience, and any domain requiring single-cell resolution analysis of gene expression.
Can RNAscope probes be integrated with other tools?
Yes, RNAscope probes can be combined with R&D Systems antibodies to provide a more comprehensive view of cellular changes.
Who is the President of Bio-Techne's Diagnostics and Spatial Biology Segment?
Dr. Matt McManus is the President, leading efforts to develop innovative solutions in the translational research landscape.
